

AMOÉBA announces the second convocation of its General Meeting

Chassieu (France), May 27, 2021 -5.45 pm- AMOÉBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and a biocontrol product for plant protection, still in a development phase, informs that the Ordinary and Extraordinary General Meeting held today at 9:00 a.m., at the Company's registered office, could not be held due to a lack of quorum for both ordinary and extraordinary resolutions.

Consequently, and in accordance with the legal provisions, the shareholders of the Company are hereby notified of the holding of an Ordinary and Extraordinary General Meeting convened on second call on Thursday 24 June 2021 at 9 a.m. at the Company's registered office, 38 avenue des Frères Montgolfier - 69680 Chassieu.

In accordance with the provisions of Articles R. 225-77 and R. 225-79 of the French Commercial Code, postal voting forms sent to the Company and proxies given for the Combined General Meeting of 27 May 2021 on the first notice of meeting shall remain valid for the Ordinary and Extraordinary General Meeting convened on the second notice of meeting on the same agenda, provided that the shares are still registered.

The notice of the second convocation including the agenda will be published in the next few days in the Bulletin des Annonces Légales Obligatoires (BALO) and published on the Company's website.

Disclaimer

In the context of the coronavirus epidemic (COVID-19), the procedures for holding the Shareholders' Meeting may change depending on health and/or legal requirements. Shareholders are invited to regularly consult the section dedicated to the Shareholders' Meeting on the Company's website (<http://www.amoeba-nature.com/Investors/General-assembly>).

About AMOÉBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection

estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on Euronext Growth. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): *Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013*

(2): *Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets*

(3): *BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017*

(4): *Biopesticides Worldwide Market 2013, CPL, Wallingford, UK*

Contacts:

Amoéba

Valérie FILIATRE

Directeur Général Adjoint

+33 4 26 69 16 00

v.filiatre@amoeba-nature.com

Calyptus

Relations investisseurs & Presse

Grégory BOSSON / Mathieu CALLEUX

+33 1 53 65 37 90 /91

amoeba@calyptus.net